| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT06104683 2022-502376-24 Details | 2024-03-27 Interventional | 2 | 0 | Pirtobrutinib Multiple Sclero… Sclerosis Relapsing Multi… | Sponsor Decision: The trial has been withdrawn with no plans to continue development. - | |||
| NCT05770531 Details | 2024-03-27 Interventional | 2 | - | Sacituzumab gov… Breast Neoplasm… Carcinoma Metastatic HER2… Metastatic Trip… | Pending calendar changes - | |||
| NCT03983668 Details | 2024-03-27 Interventional | 1/2 | - | Pembrolizumab Lymphoma | DSMC Deviation Review - | |||
| NCT05724628 Details | 2024-03-26 Interventional | 1 | 0 | Anti-Bacterial … Acute Disease Appendicitis Acute Appendici… | Project did not receive final IRB approvals. PI decided to withdrawn research study. - | |||
| NCT04779151 2020-002766-14 Details | 2024-03-26 Interventional | 2 | 51 | Dostarlimab Niraparib Adenocarcinoma Biliary Tract N… Carcinoma, Rena… Hypersensitivit… Urinary Bladder… Biliary Tract C… Clear Cell Rena… Gastric Adenoca… Gastro-oesophag… Head and Neck C… Pancreatic Duct… Platinum-sensit… Urothelial Blad… | Abandon by GSK - | |||
| NCT04172532 Details | 2024-03-26 Interventional | 1/2 | - | Peposertib Adenocarcinoma Pancreatic Neop… Locally Advance… Locally Advance… Stage II Pancre… Stage III Pancr… Unresectable Pa… | End of Initial Phase of Multi-phase protocol - | |||
| NCT04126031 2018-002800-16 Details | 2024-03-26 Interventional | 2 | 48 | Avibactam Avibactam, ceft… Ceftazidime Bacterial Infec… Gram-Negative B… Infections Gram-negative B… | Following regulatory consultation, the Sponsor has decided to terminate the study and analyze
the current dataset. The decision to terminate was solely based on a business decision, not due
to safety concerns. - | |||
| NCT03699956 Details | 2024-03-26 Interventional | 3 | 18 | Carboplatin Etoposide Carcinoma, Smal… Lung Neoplasms Small Cell Lung… Carcinoma, Smal… | RRx-001 will be studied under a new global, phase 3 clinical trial - | |||
| NCT03504774 Details | 2024-03-26 Interventional | 2 | 58 | Immunomodulatin… Food Hypersensi… Hypersensitivit… Allergy to Cash… Allergy to Shri… Allergy;Food | Study discontinued due to slow enrollment during COVID-19 pandemic Due to the COVID-19 pandemic, this study did not enroll the planned number of participants and did not meet the protocol-specified threshold for statistical significance. | |||
| NCT04762160 NCT04590820 Details | 2024-03-25 Interventional | 2 | 5 | Rituximab Lymphoma Lymphoma, Folli… Follicular Lymp… | Decision to terminate EZH-1401 was solely due to company business decision. The study was terminated early due to business reasons prior to enrolling the target number of participants needed to achieve target power and was insufficient to produce statistically reliable results and was not due to any safety concerns. No summary statistics are available given the limited data from the small number of evaluable participants and individual participant data are also not presented to protect the privacy of the individuals. | |||
| NCT04645966 2020-000948-60 Details | 2024-03-25 Interventional | 2 | 326 | Acetaminophen Meningococcal V… | The Sponsor decided to discontinue the study based on Sponsor's careful review of available
safety data in concert with the recommendation of an independent Data Monitoring Committee. Study was terminated based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee. | |||
| NCT04584684 Details | 2024-03-25 Interventional | 2 | 128 | Cetylpyridinium Ethanol Hydrogen Peroxi… Povidone COVID-19 Communicable Di… Coronavirus Inf… Infections Coronavirus Inf… Covid19 SARS-CoV-2 Infe… | The team decided to terminate the trial in order to start a new trial, unrelated to safety
reasons - | |||
| NCT03701308 Details | 2024-03-25 Interventional | 2/3 | - | Cytarabine Daunorubicin Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | End of Initial Phase of Multi-phase protocol - | |||
| NCT03257215 Details | 2024-03-25 Interventional | 4 | - | Cholecalciferol Ergocalciferols Vitamin D Vitamins Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | Recruitment very slow & funding difficult - exacerbated by COVID-19 pandemic - | |||
| NCT06326138 Details | 2024-03-22 Interventional | 1 | 0 | Edoxaban Bariatric Surge… | No support form the sponsor - | |||
| NCT05705466 Details | 2024-03-22 Interventional | 1/2 | 0 | Pembrolizumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Sponsor Decision - | |||
| NCT05625347 Details | 2024-03-22 Interventional | 1 | 4 | Aspirin Respiratory Asp… Obstructive Pul… Restrictive Pul… | The pivotal study failed to meet the primary endpoint. Without a successful readout of the
pivotal study, there was no longer a purpose for the supportive BORA-1A-C302 study. - | |||
| NCT04887831 Details | 2024-03-22 Interventional | 2 | 92 | Avelumab Carboplatin Gemcitabine Carcinoma Carcinoma, Tran… Neutropenia Urinary Bladder… Bladder Cancer Chemotherapy-in… Metastatic Blad… Myelosuppressio… Urothelial Carc… | Sponsor no longer pursuing trila for the indication. - | |||
| NCT04707625 Details | 2024-03-22 Interventional | 4 | 17 | Aflibercept Retinal Vein Oc… | IRB stopped study due to safety concerns. No further data collection and what has been
collected is not appropriate for analysis. - | |||
| NCT04691375 Details | 2024-03-22 Interventional | 1 | 86 | Pembrolizumab Adenocarcinoma … Breast Neoplasm… Carcinoma, Rena… Triple Negative… Advanced Solid … Breast Cancer Colorectal Canc… Gynecologic Can… Hormone Recepto… Lung Adenocarci… Ovarian Cancer Renal Cell Carc… Triple Negative… | Sponsor business decision. - |